植物由来医薬品のアジア市場予測

◆英語タイトル:ASIA-PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025
◆発行会社/調査会社:Inkwood Research
◆商品コード:INKW711022
◆発行日:2017年10月
◆調査対象地域:アジア
◆産業分野:製薬
◆ページ数:98
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[植物由来医薬品のアジア市場予測]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

KEY FINDINGSThe Asia-Pacific botanical and plant derivative drug market is predicted to rise at 4.10% CAGR over the forecast period of 2017-2025, generating $31578 million by its end. The market is driven by the rising investment of pharmaceutical companies, and increased integration of plant-derived drugs in the market.
MARKET INSIGHTS
The market is segmented on the basis of plant-derived drug type, products, and therapeutic applications. These drugs are less toxic in nature as compared to traditional methods. Indian botanical and plant derivative drug market is expected to exhibit the highest growth over the forecast period. A strong demand for Ayurvedic, Unani and Siddha products have contributed considerably to get a foothold for leading plant-derivative drug manufacturing companies in this region. Also, major steps have been taken towards the adoption of botanical and plant derivative drugs by the governments of other Asia-Pacific countries like Japan, South Korea, China, Australia, etc.
COMPETITIVE INSIGHTS
Abbott Pharmaceuticals, GE Healthcare, GlaxoSmithKline, Glenmark Pharmaceuticals Ltd, Piramal Phytocare Ltd. Bayer Healthcare Llc, Pfizer international, Novartis International Ag, Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd), Lupin Ltd, etc. are some of the well-known companies in the market.

*** レポート目次(コンテンツ)***

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. INDIAN BOTANICAL AND PLANT DERIVATIVE DRUGS MARKET TO OFFER GREAT OPPORTUNITIES
3.2.2. IN TERMS OF MARKET BY TYPES GLYCOSIDES SEGMENT IS GROWING RAPIDLY
3.2.3. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.4. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.3.3. INCREASING INVESTMENT IN ASIA PACIFIC
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2017-2025
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. ASIA-PACIFIC
7.1.1. CHINA
7.1.2. INDIA
7.1.3. JAPAN
7.1.4. AUSTRALIA
7.1.5. SOUTH KOREA
7.1.6. REST OF ASIA-PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.3. BIONOVA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVE
9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVE
9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVE
9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.12. PFIZER
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.14.1. OVERVIEW
9.14.2. PRODUCTION PORTFOLIO
9.14.3. STRATEGIC INITIATIVE-
9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
9.15.1. OVERVIEW
9.15.2. PRODUCTION PORTFOLIO
9.15.3. SCOT ANALYSIS

TABLE LIST
TABLE 1 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
TABLE 2 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
TABLE 3 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
TABLE 4 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
TABLE 5 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 6 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
TABLE 7 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
TABLE 8 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
TABLE 9 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
TABLE 10 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
TABLE 11 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
TABLE 12 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
TABLE 13 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
TABLE 14 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
TABLE 15 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
TABLE 16 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
TABLE 17 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
TABLE 18 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
TABLE 19 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
TABLE 20 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
TABLE 21 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)

FIGURE LIST
FIGURE 1 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 2 INDIA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 3 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
FIGURE 4 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
FIGURE 5 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
FIGURE 6 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
FIGURE 7 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
FIGURE 8 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
FIGURE 9 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
FIGURE 10 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
FIGURE 11 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
FIGURE 12 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
FIGURE 13 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
FIGURE 14 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
FIGURE 15 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
FIGURE 16 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
FIGURE 17 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
FIGURE 18 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
FIGURE 19 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
FIGURE 20 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
FIGURE 21 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
FIGURE 22 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
FIGURE 23 CHINA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 24 INDIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 25 JAPAN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 26 AUSTRALIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 27 SOUTH KOREA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 28 REST OF ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(INKW711022 )"植物由来医薬品のアジア市場予測" (英文:ASIA-PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025)はInkwood Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。